Heart Failure and a Preserved Ejection Fraction

October 13, 2010 updated by: Mayo Clinic

The Role of Vascular Dysfunction in Limiting Cardiovascular Reserve in Patients With Heart Failure and a Preserved Ejection Fraction

This will be a cross sectional study comparing patients with HFpEF and age-matched, non-HF controls recruited from the community. This design will allow for determination of biologically relevant differences in baseline ventricular and vascular function, and importantly, differences in the ability to augment ventricular and vascular function dynamically during exercise stress, when symptoms of HF typically are first noted. The endpoint of exercise-reserve function is novel and has been little examined in the existing HFpEF literature.

Study Overview

Status

Completed

Conditions

Detailed Description

Congestive heart failure (HF) is the leading cause of hospitalization among older Americans.1 Approximately half of affected patients have apparently normal systolic function (HF with preserved ejection fraction, HFpEF).2-4 In contrast to HF with low EF, there are no proven treatments for HFpEF, due largely to a lack of mechanistic understanding.4 HFpEF patients are typically older, hypertensive and female,2,3 and each of these characteristics is associated with vascular stiffening and dysfunction.5-7 Diastolic abnormalities may contribute to symptoms of exertional intolerance3,8, but non-cardiac limitations have recently been shown to be equally important.9-11 Patients with HFpEF display impaired decreases in mean vascular resistance in response to exercise, significantly limiting performance,9 yet this represents only one component of ventricular afterload. With aging and particularly in HFpEF, pulsatile load due to vascular stiffening and increased wave reflections becomes more magnified.6,12 The latter can be quantified by pulse wave velocity, arterial compliance and carotid augmentation index. These can be determined noninvasively, and while they have been shown to be abnormal in HFpEF patients at rest10,11, little is known about changes in each during exercise stress, or how this might modulate ventricular performance. Recent evidence indicates that endothelial and autonomic dysfunction are present in HFpEF9, but it is not known how these abnormalities might limit ventricular-vascular function with exercise. The primary objective of this proposal is to compare resting and exercise-induced changes in vascular function in patients with HFpEF and age-matched controls, to determine how these factors may affect exercise performance and cardiovascular reserve function.

Specific Aim 1. Contrast resting and exercise-induced changes in vascular stiffness, endothelial function, and afterload in patients with HFpEF to age-matched controls. Net, mean, and late components of afterload will be assessed by arterial elastance (Ea), systemic vascular resistance (SVR), and central augmentation index (AI). Vascular stiffness will be quantified by pulse wave velocity and total arterial compliance. Stiffness and afterload are dynamically modulated by endothelial and autonomic function, and these responses will be assessed by finger volume plethysmography. Parameters will be measured at rest, during upright cycle ergometry, and immediately post exercise by noninvasive blood pressure, tonometry and comprehensive echo-Doppler examination with tissue Doppler echo (TDE).

Specific Aim 2. Determine how baseline and exercise-induced changes in the vascular parameters measured in specific aim 1 are related to LV systolic and diastolic functional reserve, cardiac output response, metabolic exercise performance, and changes in pulmonary capillary blood volume. LV systolic and diastolic function will be assessed by echo-Doppler and TDE parameters at rest and immediately after peak exercise. Cardiac output response will be determined by the product of echo-Doppler stroke volume and heart rate. Exercise performance will quantified by expired gas analysis. Pulmonary blood volume will be estimated based upon the ratio of diffusion capacity of nitric oxide and carbon monoxide, obtained both at rest and immediately post exercise. Regression analyses will then be performed using the measured components of afterload and vascular stiffness as the independent variable and each of the above parameters as dependent output variables to delineate the role of vascular stiffening on exercise performance, reserve and ventricular-vascular coupling.

Specific Aim 3. Determine if vascular and ventricular stiffness properties measured in specific aim 1 are associated with abnormal neurohormonal responses to exercise. Blood samples will be obtained from HFpEF subjects and controls prior to and immediately after peak exercise to contrast exercise-induced changes in B-type natriuretic peptide levels and cyclic guanosine monophosphate levels.

Study Type

Observational

Enrollment (Actual)

51

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.3 There are currently >350 pre-identified subjects with HFpEF from this study who may be eligible, which will greatly enrich the recruiting process.

Control Subjects will be recruited from the community. Control subjects will be matched for age and gender to HFpEF subjects, but will have no history of HF hospitalization or significant exertional dyspnea suggestive of "preclinical" HF.

Description

Inclusion Criteria:

  • Consultation by a cardiologist for HF in the past 1 year
  • (HF rigorously defined by the modified Framingham criteria9),
  • able to exercise on a treadmill

Exclusion Criteria:

  • decompensated HF; significant valvular disease; infiltrative, restrictive, or hypertrophic cardiomyopathy; cor pulmonale or significant pulmonary limitation; unstable coronary disease; atrial fibrillation; pregnancy; inability to exercise or suspend vasoactive medicines for at least 24 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
Single visit exercise study
Other Names:
  • Standard metabolic stress testing.
  • Pulmonary Capillary Blood Volume.
  • Plasma and Serum Neurohormone levels.
  • Ventricular data determined from echo-Doppler.
  • Vascular data obtained using a radial tonometry device
2
CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
Single visit exercise study
Other Names:
  • Standard metabolic stress testing.
  • Pulmonary Capillary Blood Volume.
  • Plasma and Serum Neurohormone levels.
  • Ventricular data determined from echo-Doppler.
  • Vascular data obtained using a radial tonometry device
3 Healthy normal adults
No identifiable cardiac issues at time of exercise.
Single visit exercise study
Other Names:
  • Standard metabolic stress testing.
  • Pulmonary Capillary Blood Volume.
  • Plasma and Serum Neurohormone levels.
  • Ventricular data determined from echo-Doppler.
  • Vascular data obtained using a radial tonometry device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Contrast resting and exercise-induced changes in vascular stiffness, endothelial function, and afterload in patients with HFpEF to age-matched controls.
Time Frame: Throughout single visit.
Throughout single visit.

Secondary Outcome Measures

Outcome Measure
Time Frame
Determine how baseline and exercise-induced changes in the vascular parameters measured are related to LV systolic and diastolic functional reserve, cardiac output response, metabolic exercise performance, and changes in pulmonary cap
Time Frame: Throughout single visit
Throughout single visit
Determine if vascular and ventricular stiffness properties measured in specific aim 1 are associated with abnormal neurohormonal responses to exercise.
Time Frame: Immediately pre and post exercise
Immediately pre and post exercise

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Barry A. Borlaug, MD, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2007

Primary Completion (Actual)

June 1, 2009

Study Completion (Actual)

June 1, 2009

Study Registration Dates

First Submitted

December 21, 2007

First Submitted That Met QC Criteria

December 21, 2007

First Posted (Estimate)

January 7, 2008

Study Record Updates

Last Update Posted (Estimate)

October 14, 2010

Last Update Submitted That Met QC Criteria

October 13, 2010

Last Verified

October 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on O2 consumption max bike test

3
Subscribe